Eledon Pharma DEF 14A: Executive Compensation Details

TL;DR

Eledon Pharma's DEF 14A drops, showing exec comp details & award values for 2023.

AI Summary

Eledon Pharmaceuticals, Inc. filed a DEF 14A on May 30, 2024, detailing executive compensation and corporate governance matters. The filing includes information on the fair value of awards granted to executive officers, such as those granted in fiscal year 2023, and changes in the fair value of outstanding awards. The company, formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc., is headquartered in Irvine, CA.

Why It Matters

This filing provides insight into how Eledon Pharmaceuticals compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.

Risk Assessment

Risk Level: medium — DEF 14A filings are routine disclosures, but they can reveal information about executive compensation and corporate actions that may impact stock value.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period for executive compensation details)
• 20240530 — Filing Date (Date the DEF 14A was submitted to the SEC)

Key Players & Entities

• Eledon Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
• Novus Therapeutics, Inc. (company) — Former name of Eledon Pharmaceuticals
• Tokai Pharmaceuticals Inc (company) — Former name of Eledon Pharmaceuticals
• Irvine, CA (location) — Company headquarters

FAQ

Key Financial Figures

• $13.1 billion — ganization culminating in the company's $13.1 billion 6 acquisition by Bristol Myers Squi

Filing Documents

• eldn-20240530.htm (DEF 14A) — 1175KB
• img117103358_0.jpg (GRAPHIC) — 187KB
• img117103358_1.jpg (GRAPHIC) — 140KB
• img117103358_2.jpg (GRAPHIC) — 137KB
• img117103358_3.jpg (GRAPHIC) — 915KB
• img117103358_4.jpg (GRAPHIC) — 508KB
• 0000950170-24-066564.txt ( ) — 6325KB
• eldn-20240530.xsd (EX-101.SCH) — 21KB
• eldn-20240530_htm.xml (XML) — 301KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 20 Summary Compensation Table 20 Agreements with Named Executive Officers 23 Outstanding Equity Awards at Fiscal Year End 2023 26 Pay versus Performance Table 27 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 31 DIRECTOR COMPENSATION 32 STOCK OWNERSHIP AND REPORTING 34 REPORT OF THE AUDIT COMMITTEE OF THE BOARD 36 MATTERS TO BE VOTED ON 37 Proposal 1: Election of Directors 37 Proposal 2: Approval of Amendment to 2020 Incentive Plan to Increase the Aggregate Number of Shares Available for Issuance Thereunder 37 Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm 46 Audit Fees and Services 46 Pre-Approval Polices and Procedures 46 OTHER MATTERS 48 APPENDIX A – Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan A- 1

Forward-Looking Statements

Forward-Looking Statements This Proxy Statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. Any statements other than statements of historical or current fact are forward looking statements, and may in some instances be identified by the use of words such as "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of our capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause our actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly reports on Form 10-Q, annual report on Form 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this Proxy Statement speak only as of the date hereof and not of any future date, and we expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. QUESTIONS AND ANSWERS ABOUT THESE PROXY MA TERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? We sent you th

View Full Filing

View this DEF 14A filing on SEC EDGAR